Mestinon is the brand name for the drug pyridostigmine bromide. It is used primarily to improve muscle strength in patients with myasthenia gravis. The medication belongs to a class of cholinesterase inhibitors that increase the availability of acetylcholine at the neuromuscular junction. By blocking the enzyme acetylcholinesterase, it prevents the breakdown of acetylcholine, allowing more of the neurotransmitter to remain active. The prolonged presence of acetylcholine enhances stimulation of muscle receptors, leading to stronger and more sustained muscle contractions. This therapeutic effect helps alleviate the fatigue and weakness characteristic of the disease. The drug is administered orally in tablet form and its effects typically begin within a few hours after dosing. Its duration of action can be adjusted by varying the dose and timing to match the patient's symptom pattern.

Mestinon is the commercial name for pyridostigmine bromide, an acetylcholinesterase inhibitor. It is prescribed primarily to improve muscle strength in patients with myasthenia gravis and to lower intraocular pressure in certain glaucomas. The drug works by blocking the enzyme acetylcholinesterase that normally breaks down acetylcholine. This inhibition prevents the rapid degradation of acetylcholine at the neuromuscular junction. Consequently, acetylcholine remains available to stimulate muscle fibers more effectively. Increased stimulation leads to stronger and more coordinated muscle contractions. The resulting reduction of clinical symptoms is the therapeutic aim of the medication.

Mestinon is a medication commonly used to manage symptoms of myasthenia gravis. Patients may experience mild gastrointestinal discomfort such as nausea or abdominal cramping. Some individuals report increased sweating, especially during hot weather or physical activity. Muscle cramps or weakness can occur as the body adjusts to the drug. Headaches are occasionally noted and are generally mild to moderate in intensity. Occasional dizziness or light-headedness may be reported, particularly after dose changes. Sleep disturbances, including vivid dreams or difficulty falling asleep, have been observed in some patients. These reactions are generally transient and tend to improve with continued use or dose adjustment.

Common reactions to Mestinon include muscle cramps. Patients may experience weakness especially in the limbs. Fatigue is also reported frequently. Increased salivation or tearing can occur. Abdominal discomfort or nausea may be observed. These effects are generally mild and often improve with continued use.